-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$105.8052.23% Upside
Recent Analyst Forecasts and Stock Ratings
BioMarin Pharmaceutical Inc. Frequently Asked Questions
-
What analysts cover BioMarin Pharmaceutical Inc.?
BioMarin Pharmaceutical Inc. has been rated by research analysts at Barclays, Citigroup, Scotiabank, Truist Financial, Bernstein, BMO Capital in the past 90 days.